阿比特龙联合泼尼松治疗未经化疗转移性去势抵抗性前列腺癌患者的有效性和安全性探讨

Efficacy and safety of abiraterone combined with prednisone in the treatment of non-chemotherapy metastatic castration-resistant prostate cancer

目的研究阿比特龙联合泼尼松治疗未经化疗转移性去势抵抗性前列腺癌患者的有效性和安全性。方法采用回顾性分析方法,研究对象为2018年1月至2020年1月都江堰市人民医院收治入院的60例未经化疗转移性去势抵抗性前列腺癌患者,根据治疗方法不同分为对照组(单用泼尼松治疗,n=30)和研究组(联用泼尼松与阿比特龙治疗,n=30)。比较2组患者治疗前后生活质量评分、最大尿流率、剩余尿量、睾酮及血清总前列腺特异性抗原水平与治疗后近期总有效率、不良反应发生率。结果治疗前,2组患者生活质量评分、最大尿流率、剩余尿量、睾酮及血清总前列腺特异性抗原水平比较,差异均无统计学意义(P>0.05)。治疗后,2组患者生活质量评分、最大尿流率较治疗前明显提高,剩余尿量、血清总前列腺特异性抗原水平较治疗前明显降低,差异均有统计学意义(P<0.05);且研究组生活质量评分、最大尿流率明显高于对照组,剩余尿量、血清总前列腺特异性抗原水平明显低于对照组,差异均有统计学意义(P<0.05)。研究组患者的总有效率(83.33%)明显高于对照组(53.33%),差异有统计学意义(P<0.05)。研究组患者治疗后不良反应发生率(13.33%)与对照组(16.67%)比较,差异无统计学意义(P>0.05)。结论阿比特龙联合泼尼松治疗未经化疗转移性去势抵抗性前列腺癌患者的临床效果显著,可有效抑制前列腺癌细胞生长与疾病进展,且不良反应较少,安全性高。

Objective To study the effectiveness and safety of abiraterone combined with prednisone in the treatment of patients with metastatic castration-resistant prostate cancer without chemotherapy. Methods A retrospective analysis method were used,the subjects of the study were 60 patients with metastatic castration-resistant prostate cancer who were admitted to Dujiangyan People’s Hospital from January 2018 to January 2020. They were divided into control groups(prednisone alone,n = 30) and the study group(combined treatment with prednisone and abiraterone,n = 30) according to different treatment methods. The quality of life score,maximum urine flow rate,remaining urine volume,testosterone and serum total prostate specific antigen levels of the two groups of patients before and after treatment were compared and the total effective rate and the incidence of adverse reaction rate after treatment were compared. Results Before treatment,there was no statistically significant difference in the quality of life score,maximum urine flow rate,remaining urine volume,testosterone and serum total prostate specific antigen levels between the two groups of patients(P>0.05). After treatment,the quality of life scores and maximum urine flow rate of the two groups of patients were significantly higher than before treatment,and the remaining urine volume and serum total prostate specific antigen levels were significantly lower than before treatment,and the differences were statistically significant(P<0.05);and the quality of life score,maximum urine flow rate of the study group were significantly higher than those of the control group,the remaining urine volume and serum total prostate specific antigen levels were significantly lower than those of the control group,and the differences were statistically significant(P<0.05). The total effective rate of the study group(83. 33%) was significantly higher than that of the control group(53. 33%),and the difference was statistically significant(P< 0. 05). There was no statistically significant difference in the incidence of adverse reactions between the study group(13. 33%) and the control group(16. 67%) after treatment(P>0.05). Conclusion Abiraterone combined with prednisone has a significant effect in the treatment of m CRPC patients without chemotherapy. It can effectively inhibit the growth of prostate cancer cells and disease progression,with fewer adverse reactions and high safety.